Phase 2, Randomized, Open-Label Study comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects with Newly Diagnosed Multiple Myeloma Eligible for High dose chemo
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
October 11, 2017
End Date
June 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
October 11, 2017
End Date
June 30, 2022